about
Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.[Acneiforme rash in woman with pulmonary adenocarcinoma].Durvalumab in non-small-cell lung cancer patients: current developments.Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis.Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.The role of brigatinib in crizotinib-resistant non-small cell lung cancer.Progress in the Management of Advanced Thoracic Malignancies in 2017.Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.Congenital Bronchial Artery to Pulmonary Artery Fistula in a Patient With Lung Cancer Involving the Carina.Acrometastasis as the initial presentation of lung adenocarcinoma in a young woman.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Durvalumab for the treatment of non-small cell lung cancerNeutrophilia as prognostic biomarker in locally advanced stage III lung cancerCorrection: C797S, T790M and sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCRProlonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer PatientsNivolumab-induced pneumonitis complicated by cyst formationPseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with NivolumabImmune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendationsBrief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni SyndromeDiverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerImpact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerCirculating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsHyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyOutcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsHepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLCRecent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide ProcessingActivity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesImmune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryNon-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer PatientsSurvival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsAcquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung CancerLetter to the Editor about Sorich et alSafety of osimertinib in EGFR-mutated non-small cell lung cancer
P50
Q38847533-EAAA23B3-695B-4A6E-93DD-E9C01804A8EBQ42344252-2769F14E-CAB1-4634-8588-10929D45EDC1Q46611263-5ED81D82-49C8-4FC2-B957-5620EDB70D58Q47593976-69E18674-3034-49E9-B45B-ABA98B0D3ED7Q47903564-994FCAB6-4A07-40C3-9294-6D8DFB5169D9Q47956599-843E5250-E85C-46CD-8692-D40CD87D003CQ48373246-CDB40C08-C0B3-4C6D-9BBC-5A2F2B29B35EQ48512265-5A290A90-9ABC-4980-9B32-B03DB26DCA69Q50054820-64987396-BF64-4BED-B6D8-100B253E494AQ50074196-7FCCEFA0-B531-45B2-9C69-0B4196F28690Q51545707-1A551B7E-E7BD-4B59-998C-ADB453A4869EQ53248863-E9EDAFF3-C905-436C-A902-92AD0C6CD697Q55284597-57F97B3D-2FE1-4EC4-8AA5-0301970E55FAQ56890629-D7E3C876-2C84-4D07-9593-12E504C58563Q57286032-5548AB1B-635D-48D3-94CD-9400987539D1Q64246984-B468DF66-4B7F-47D4-9CC3-362F327E8B2DQ89049584-E576AFCF-9865-4026-9996-35C649532587Q89142478-1FF14E28-E605-4849-8A72-946BA4B9E405Q90287233-0EBFA7AB-6AD5-463E-BFBF-FF4C178AD1BAQ90367675-8FD8911F-A200-434C-9E38-FDB25DE8A1C4Q90367680-2DF4D61A-32DC-4D36-A460-DF3EC594BEBAQ90493702-3B1B1800-4F0F-44FB-80CD-E79E91EE4607Q91038984-DE03670A-1EA2-48FD-AF98-54536CD63593Q91069251-D4869F29-FB2C-4C69-A815-B477CD83F6A0Q91332386-C37A7D43-800B-4852-BD8B-7C02B7534E82Q91704817-F13ACBE8-E9EC-4D2B-AAF0-E031A298A7C8Q91853479-1D967021-6097-4FC9-BB34-E42A9AFCF55DQ92106808-46980335-DE12-4C4E-84B5-77AD0EEEED43Q92159290-1996F4B8-6693-421D-8A0C-FD711F6FA01BQ92267950-5ECBFAF7-E0BC-459F-B506-CB5D55B0A3BDQ92283535-EAB938F8-93C8-402A-A1A0-8F0654DF519DQ92449292-776D09E0-B8CF-4948-9FFB-ADDF9380B6F5Q92774133-6490CA35-384A-4833-B5AD-6D69A1C62C5EQ92794518-B67B1195-4F0E-4DFB-8010-82730462A711Q92843745-196695EF-8F43-4200-A38A-32951ADA4425Q93239523-C58F8723-F6C6-4AB0-8A99-8E1304003D00
P50
description
researcher ORCID ID = 0000-0003-0936-7338
@en
name
Laura Mezquita
@ast
Laura Mezquita
@en
Laura Mezquita
@es
Laura Mezquita
@nl
type
label
Laura Mezquita
@ast
Laura Mezquita
@en
Laura Mezquita
@es
Laura Mezquita
@nl
prefLabel
Laura Mezquita
@ast
Laura Mezquita
@en
Laura Mezquita
@es
Laura Mezquita
@nl
P106
P1153
57195590807
P21
P31
P496
0000-0003-0936-7338